HCW Biologics Inc. (HCWB)

Market Cap	35.83M
Revenue (ttm)	3.50M
Net Income (ttm)	-37.33M
Shares Out	37.82M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,173,231
Open	0.930
Previous Close	1.100
Day's Range	0.810 - 1.110
52-Week Range	0.276 - 2.520
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About HCWB

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2021
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: HCWB
• Website: https://www.hcwbiologics.com

Financial Performance

In 2023, HCW Biologics's revenue was $2.84 million, a decrease of -57.72% compared to the previous year's $6.72 million. Losses were -$24.99 million, 67.7% more than in 2022.